CAR-T Cell Therapy for Non-Hodgkin’s Lymphoma Market Size of CAR T Cell Therapy for Non-Hodgkin's Lymphoma in the 6MM is anticipated to be USD 2796.2 Million in 2030. Diffuse large B-cell Lymphoma (DLBCL) is the most common type of NHL, accounting for about 22% of newly diagnosed cases of B-cell NHL in the united states. Advancements in technology, Increased collaborations & acquisitions and Competition among biotech & pharma giants are some of the factors expected to drive the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market in the coming years. The key players in the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market include Novartis, Kite Pharma, Gilead Sciences, Celgene Corporation and others. For more details visit: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-non-hodgkins-lymphoma-market #CARTCellTherapy #CellTherapy #CART #Lymphoma #NonHodgkinLymphoma